Could a single infusion of modified immune cells tame lupus kidney flares?
NCT ID NCT07053800
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a one-time treatment called Obe-cel, made from a patient's own immune cells, for severe lupus nephritis that hasn't improved with standard care. About 35 people aged 12 to 65 will receive the infusion and be monitored for up to 24 months. The main goal is to see if the treatment can make signs of kidney disease disappear within 6 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Obe-cel (obecabtagene autoleucel), a CAR T-cell therapy
What this could lead to
If it works, this could point toward a new treatment option for people with severe lupus nephritis who haven't responded to other therapies.
What could go wrong
This is an early Phase 2 trial with only 35 participants, so results may not apply to everyone. CAR T-cell therapy can have serious side effects, and long-term safety is unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUPUS NEPHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Addenbrooke's Hospital
RECRUITINGCambridge, CB2 0QQ, United Kingdom
Contact Email: •••••@•••••
-
Bristol Haematology and Oncology Centre
RECRUITINGBristol, BS1 3LH, United Kingdom
Contact Email: •••••@•••••
-
Great Ormond Street Hospital
RECRUITINGLondon, WC1N 3JH, United Kingdom
-
Manchester Royal Infirmary
RECRUITINGManchester, M13 9WL, United Kingdom
-
Queen Elizabeth Hospital Birmingham
RECRUITINGBirmingham, B15 2TH, United Kingdom
Contact Email: •••••@•••••
-
Queen Elizabeth University Hospital
RECRUITINGGlasgow, G51 4TF, United Kingdom
Contact Email: •••••@•••••
-
State University of New York Upstate Medical Center (SUNY)
RECRUITINGSyracuse, New York, 13210, United States
-
Texas Transplant Institute
RECRUITINGSan Antonio, Texas, 78229, United States
-
University College Hospital
RECRUITINGLondon, MW1 2PG, United Kingdom
-
Western General Hospital Edinburgh
RECRUITINGEdinburgh, EH4 2XU, United Kingdom
Contact Email: •••••@•••••